Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...
neffy is a compact nasal spray, designed to provide rapid absorption of adrenaline (epinephrine ... and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who ...
Although ARS Pharmaceuticals’ approval for its epinephrine nasal spray came later than expected, the company ultimately received a ... Specifically, the FDA approved Neffy 2 mg for treatment of Type 1 ...